Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease

Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infecte...

Descripción completa

Detalles Bibliográficos
Autores principales: AlQahtani, Manaf, Kumar, Nitya, Aljawder, Dhuha, Abdulrahman, Abdulkarim, Mohamed, Mohammed Wael, Alnashaba, Fatema, Fayyad, Mohammed Abu, Alshaikh, Faisal, Alsahaf, Fatima, Saeed, Sawsan, Almahroos, Amal, Abdulrahim, Zainab, Otoom, Sameer, Atkin, Stephen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943168/
https://www.ncbi.nlm.nih.gov/pubmed/35322077
http://dx.doi.org/10.1038/s41598-022-08794-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943168/
https://www.ncbi.nlm.nih.gov/pubmed/35322077
http://dx.doi.org/10.1038/s41598-022-08794-w

Ejemplares similares